Literature DB >> 1721355

Posttransplant lymphoproliferative disorders occurring under primary FK 506 immunosuppression.

J Reyes1, A Tzakis, M Green, B Nour, M Nalesnik, D Van Thiel, M Martin, M K Breinig, J J Fung, M Cooper.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1991        PMID： 1721355      PMCID： PMC2975614     

Source DB:  PubMed          Journal:  Transplant Proc        ISSN： 0041-1345            Impact factor:   1.066


× No keyword cloud information.
  4 in total

1.  Lymphoproliferative disorders arising under immunosuppression with FK 506: initial observations in a large transplant population.

Authors:  M A Nalesnik; A J Demetris; J J Fung; T E Starzl
Journal:  Transplant Proc       Date:  1991-02       Impact factor: 1.066

2.  Malignant lymphomas in transplantation patients.

Authors:  I Penn; W Hammond; L Brettschneider; T E Starzl
Journal:  Transplant Proc       Date:  1969-03       Impact factor: 1.066

3.  The pathology of posttransplant lymphoproliferative disorders occurring in the setting of cyclosporine A-prednisone immunosuppression.

Authors:  M A Nalesnik; R Jaffe; T E Starzl; A J Demetris; K Porter; J A Burnham; L Makowka; M Ho; J Locker
Journal:  Am J Pathol       Date:  1988-10       Impact factor: 4.307

4.  Cancers following cyclosporine therapy.

Authors:  I Penn
Journal:  Transplantation       Date:  1987-01       Impact factor: 4.939
  4 in total
  8 in total

Review 1.  FK 506 and autoimmune disease: perspective and prospects.

Authors:  A W Thomson; T E Starzl
Journal:  Autoimmunity       Date:  1992       Impact factor: 2.815

2.  Kaposi's sarcoma in two primary liver allograft recipients occurring under FK506 immunosuppression.

Authors:  Zaklyah Kadry; Oscar Bronsther; David H Van Thiel; Parmjeet Randhawa; John J Fung; Thomas E Starzl
Journal:  Clin Transplant       Date:  1993-01-01       Impact factor: 2.863

3.  Rubella infection after orthotopic liver transplantation.

Authors:  G V Mazariegos; M Green; J Reyes; B Nour; A Tzakis; T E Starzl
Journal:  Pediatr Infect Dis J       Date:  1994-02       Impact factor: 2.129

4.  Lymphoproliferative disease after intestinal transplantation under primary FK 506 immunosuppression.

Authors:  J Reyes; A G Tzakis; H Bonet; M Green; E Yunis; M Nalesnik; B Nour; S Kocoshis; K Abu-Elmagd; S Todo
Journal:  Transplant Proc       Date:  1994-06       Impact factor: 1.066

5.  Two-year experience with FK 506 in pediatric patients.

Authors:  A G Tzakis; J Reyes; S Todo; B Nour; R Shapiro; M Jordan; J McCauley; J Armitage; J J Fung; T E Starzl
Journal:  Transplant Proc       Date:  1993-02       Impact factor: 1.066

6.  What have we learned about primary liver transplantation under tacrolimus immunosuppression? Long-term follow-up of the first 1000 patients.

Authors:  A Jain; J Reyes; R Kashyap; S Rohal; K Abu-Elmagd; T Starzl; J Fung
Journal:  Ann Surg       Date:  1999-09       Impact factor: 12.969

Review 7.  Tacrolimus. A review of its pharmacology, and therapeutic potential in hepatic and renal transplantation.

Authors:  D H Peters; A Fitton; G L Plosker; D Faulds
Journal:  Drugs       Date:  1993-10       Impact factor: 9.546

8.  Recent advances in hepatic transplantation at the University of Pittsburgh.

Authors:  K Abu-Elmagd; O Bronsther; A Jain; W Irish; H Ramos; I R Marino; F Dodson; R Selby; H Doyle; H Furukawa
Journal:  Clin Transpl       Date:  1993
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.